Q2043 Sipuleucel-t auto cd54+
Also known as: Provenge, sipuleucel-T, autologous cell therapy
Sipuleucel-T autologous CD54+ T-cell antigen presenting cell therapy for castration-resistant prostate cancer.
In Plain Language
prostate cancer vaccine; personalized immune therapy
Clinical Context
Personalized vaccine therapy for asymptomatic or minimally symptomatic castration-resistant prostate cancer. Requires apheresis collection and ex vivo cell processing.
RVU Information
CPT Q2043 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q2043?
CPT Q2043 (Sipuleucel-t auto cd54+) is a Q Codes code. Sipuleucel-T autologous CD54+ T-cell antigen presenting cell therapy for castration-resistant prostate cancer.
Is Q2043 covered by insurance?
Q2043 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Personalized vaccine therapy for asymptomatic or minimally symptomatic castration-resistant prostate cancer. Requires apheresis collection and ex vivo cell processing.
When is CPT Q2043 used?
Personalized vaccine therapy for asymptomatic or minimally symptomatic castration-resistant prostate cancer. Requires apheresis collection and ex vivo cell processing.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.